GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Regencell Bioscience Holdings Ltd (NAS:RGC) » Definitions » Short-Term Debt

RGC (Regencell Bioscience Holdings) Short-Term Debt : $0.00 Mil (As of Jun. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Regencell Bioscience Holdings Short-Term Debt?

Regencell Bioscience Holdings's Short-Term Debt for the quarter that ended in Jun. 2024 was $0.00 Mil.


Regencell Bioscience Holdings Short-Term Debt Historical Data

The historical data trend for Regencell Bioscience Holdings's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regencell Bioscience Holdings Short-Term Debt Chart

Regencell Bioscience Holdings Annual Data
Trend Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Short-Term Debt
Get a 7-Day Free Trial 3.07 3.68 - - -

Regencell Bioscience Holdings Semi-Annual Data
Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only - - - - -

Regencell Bioscience Holdings Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.


Regencell Bioscience Holdings Short-Term Debt Related Terms

Thank you for viewing the detailed overview of Regencell Bioscience Holdings's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.


Regencell Bioscience Holdings Business Description

Traded in Other Exchanges
N/A
Address
29 Leighton Road, 9/F Chinachem Leighton Plaza, Causeway Bay, Hong Kong, HKG
Regencell Bioscience Holdings Ltd is a bioscience company focusing on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degenerations, specifically ADHD and ASD, and infectious diseases affecting people's immune systems.